The partner companies Pfizer (USA) and BioNTech (Germany), as they announced, will test a third dose of 3 μg (micrograms) of their coronavirus vaccine in children under the age of five.
According to their announcement, the two doses of their vaccine tested in children two, three and four years old, failed trigger an immune response comparable to that in adolescents and adults. However, the vaccine failed to elicit an immune response in children from six months to two years.
The two companies assured that “no security issues were detectedStressing at the same time that the decision to evaluate a third installment in children aged six months to five years reflects the commitment of companies to choose carefully the correct dose, so that optimize the risk-benefit profile“.
The “blind” clinical study will now include a third dose at least two months after the second dose, with the aim of increasing the protection of children up to five years old. If all three doses are successful, The companies announced that they will submit their test data to regulators within the first half of 2022, so that they can receive an urgent marketing authorization for their vaccine in young children.
At the same time, they announced that they plan to try a third dose of 10 μg in children five to 12 years of age.
Finally, they started a sub-study third dose of 10 or 30 μg in 600 adolescents 12 – 17 years. These tests are related to the appearance of the new variant Ομικρον and the initial findings that people who take booster doses have a greater degree of protection.
See also: US: Committee of Experts set up: Pfizer and Moderna preferred over J&J